1. |
Global initiative for chronic obstructive lung disease, 2023.
|
2. |
Safiri S, Carson-Chahhoud K, Noori M, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019. BMJ, 2022, 378: e069679.
|
3. |
Güder G, Störk S. COPD and heart failure: differential diagnosis and comorbidity. Herz, 2019, 44(6): 502-508.
|
4. |
Ingebrigtsen TS, Marott JL, Vestbo J, et al. Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap. BMJ Open Respir Res, 2020, 7(1): e000470.
|
5. |
Axson EL, Ragutheeswaran K, Sundaram V, et al. Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. Respir Res, 2020, 21(1): 54.
|
6. |
Kaszuba E, Odeberg H, Råstam L, et al. Impact of heart failure and other comorbidities on mortality in patients with chronic obstructive pulmonary disease: a register-based, prospective cohort study. BMC Fam Pract, 2018, 19(1): 178.
|
7. |
Xu S, Ye Z, Ma J, et al. The impact of chronic obstructive pulmonary disease on hospitalization and mortality in patients with heart failure. Eur J Clin Invest, 2021, 51(1): e13402.
|
8. |
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 2021, 42(36): 3599-3726.
|
9. |
Karoli NA, Borodkin AV, Kosheleva NA, et al. Prognostic markers for the development of adverse outcomes in patients with chronic obstructive pulmonary disease and chronic heart failure. Kardiologiia, 2018, 58(Suppl 9): 39-47.
|
10. |
Sessa M, Mascolo A, Mortensen RN, et al. Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. Eur J Heart Fail, 2018, 20(3): 548-556.
|
11. |
Andrijevic L, Milutinov S, Andrijevic I, et al. Association between the inflammatory biomarkers and left ventricular systolic dysfunction in patients with exacerbations of chronic obstructive pulmonary disease. Balkan Med J, 2017, 34(3): 226-231.
|
12. |
Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J, 2005, 26(18): 1887-1894.
|
13. |
Lagan J, Schelbert EB, Naish JH, et al. Mechanisms underlying the association of chronic obstructive pulmonary disease with heart failure. JACC Cardiovasc Imaging, 2021, 14(10): 1963-1973.
|
14. |
Cao Y, Xing Z, Long H, et al. Predictors of mortality in COPD exacerbation cases presenting to the respiratory intensive care unit. Respir Res, 2021, 22(1): 77.
|
15. |
Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J, 2006, 28(6): 1245-1257.
|
16. |
Gevaert AB, Tibebu S, Mamas MA, et al. Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes. ESC Heart Fail, 2021, 8(4): 2741-2754.
|
17. |
Mao Z, Zhong Y. Prognostic risk factors in patients with refractory heart failure treated with continuous veno-venous hemofiltration. Ther Apher Dial, 2022, 26(6): 1106-1113.
|
18. |
Tromp J, Bamadhaj S, Cleland JGF, et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Glob Health, 2020, 8(3): e411-e422.
|
19. |
Sliwa K, Davison BA, Mayosi BM, et al. Readmission and death after an acute heart failure event: predictors and outcomes in sub-Saharan Africa: results from the THESUS-HF registry. Eur Heart J, 2013, 34(40): 3151-3159.
|
20. |
Sherwood A, Blumenthal JA, Hinderliter AL, et al. Worsening depressive symptoms are associated with adverse clinical outcomes in patients with heart failure. J Am Coll Cardiol, 2011, 57(4): 418-423.
|
21. |
Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health study): a national cross-sectional study. Lancet, 2018, 391(10131): 1706-1717.
|
22. |
Easter M, Bollenbecker S, Barnes JW, et al. Targeting aging pathways in chronic obstructive pulmonary disease. Int J Mol Sci, 2020, 21(18): 6924.
|
23. |
Banerjee A, Pasea L, Chung SC, et al. A population-based study of 92 clinically recognized risk factors for heart failure: co-occurrence, prognosis and preventive potential. Eur J Heart Fail, 2022, 24(3): 466-480.
|
24. |
Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev, 2013, 22(130): 454-475.
|
25. |
Vodovar N, Logeart D. Similar BNP and mortality association in patients with and without heart failure: any increase matters. J Am Coll Cardiol, 2018, 71(19): 2089-2091.
|
26. |
Stolz D, Breidthardt T, Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest, 2008, 133(5): 1088-1094.
|
27. |
Zhang X, Wang S, Liu J, et al. D-dimer and the incidence of heart failure and mortality after acute myocardial infarction. Heart, 2021, 107(3): 237-244.
|
28. |
Li H, Zeng Z, Cheng J, et al. Prognostic role of NT-proBNP for in-hospital and 1-year mortality in patients with acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis, 2020, 15: 57-67.
|